Condition
Fatty Liver Disease
Locations
Canada
Start date
08/10/2025
Identifiers
Trial ID NN4005-8221,
NCT number NCT07214870,
Eudract number Not Available
NCT number NCT07214870,
Eudract number Not Available
Summary
The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat. Participants will receive either NNC4005-0001, which is the treatment being tested, or a placebo, which is a treatment that contains no active medicine. The study will last for about for about 7 to 8 months.
Trial Overview:
Treatment
DRUG: NNC4005-001
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Oct 08 2025 - May 14 2027
Participants
60
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 69 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.